Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access advanced solid tumors specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced solid tumors treatment provided free
This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.
Sponsor: Eikon Therapeutics
Check if you qualify for this advanced solid tumors clinical trial in San Francisco, CA
If you're searching for advanced solid tumors treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.